ELAB

Elevai Labs (ELAB)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ELAB
DataOraFonteTitoloSimboloCompagnia
02/05/202414:30GlobeNewswire Inc.Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of ObesityNASDAQ:ELABElevai Labs Inc
01/05/202422:00GlobeNewswire Inc.Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome SkincareNASDAQ:ELABElevai Labs Inc
01/05/202415:00GlobeNewswire Inc.Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity TreatmentsNASDAQ:ELABElevai Labs Inc
29/04/202415:45GlobeNewswire Inc.Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue CommitmentsNASDAQ:ELABElevai Labs Inc
22/04/202414:00GlobeNewswire Inc.ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 MonthsNASDAQ:ELABElevai Labs Inc
29/03/202417:00GlobeNewswire Inc.Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial ResultsNASDAQ:ELABElevai Labs Inc
18/03/202413:51InvestorsHub NewsWireElevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical MarketNASDAQ:ELABElevai Labs Inc
24/01/202414:30GlobeNewswire Inc.ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark OfficeNASDAQ:ELABElevai Labs Inc
17/01/202415:07InvestorsHub NewsWireELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global ReachNASDAQ:ELABElevai Labs Inc
16/01/202416:05InvestorsHub NewsWireELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing TechnologyNASDAQ:ELABElevai Labs Inc
02/01/202415:15GlobeNewswire Inc.ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry ConferencesNASDAQ:ELABElevai Labs Inc
11/12/202315:15GlobeNewswire Inc.Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023NASDAQ:ELABElevai Labs Inc
07/12/202315:41GlobeNewswire Inc.ELEVAI Labs, Inc. Expands International Distribution into EuropeNASDAQ:ELABElevai Labs Inc
29/11/202315:00GlobeNewswire Inc.Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics ProductsNASDAQ:ELABElevai Labs Inc
24/11/202319:38PR Newswire (US)ELEVAI Labs, Inc. Announces Closing of $6,000,000 Initial Public OfferingNASDAQ:ELABElevai Labs Inc
24/11/202318:00GlobeNewswire Inc.Univest Securities, LLC Announces Closing of $6 Million Initial Public Offering of Common Stock for its Client ELEVAI Labs Inc. (Nasdaq: ELAB)NASDAQ:ELABElevai Labs Inc
23/06/200523:13Business WireEon Labs Receives Final Approval for Bupropion HCl, ER 200mg Tablets and Will Begin Shipping ImmediatelyNASDAQ:ELABElevai Labs Inc
13/06/200523:41Business WireAppeals Court Affirms that Eon Labs' Itraconazole Does Not Infringe Janssen's PatentNASDAQ:ELABElevai Labs Inc
24/02/200420:34PR Newswire (US)Pacific Exchange to Trade Six New OptionsNASDAQ:ELABElevai Labs Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ELAB
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network